Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monitoring Dupilumab Response in Atopic Dermatitis with Noninvasive Imaging
NCT05265234Phase 4Unknown
- Sponsor
- OptiSkin Medical
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in atopic dermatitis (AD), sponsored by OptiSkin Medical. Status: unknown.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05265234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265234.